Zepbound Cost Without Insurance in 2026: Telehealth Options Compared
Compare reviewed GLP-1 weight loss providers, billing commitments, and the treatments their links actually offer.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Compare the options first
Full comparison & price terms ↓A short preview in editorial order—not a guarantee of the cheapest total bill. Read the commitment terms before choosing.
The Ranking
SkinnyRx
Clinician-guided GLP-1 platform with both compounded and brand-name access plus overnight shipping.
Editor’s take: Premium positioning, premium catalog. If you want maximum optionality across GLP-1 modalities, this is the deepest menu on the site. The premium catalog comes at a premium price. If you want maximum optionality across GLP-1 modalities, SkinnyRx is the deepest menu on the site; if you want the lowest cost, look at Trimi or HealthRx.
Full review →
Shed Rx
GLP-1 clinic offering injections, oral semaglutide, drops, and lozenges plus brand-name Wegovy and Zepbound.
Editor’s take: A reasonable mid-priced pick when delivery flexibility matters. Verify auto-billing terms before signing up given mixed reports. Verify auto-billing terms before signing up given mixed reviews on cancellation. If delivery flexibility is your priority, compare ShedRx against Breeze Meds which also offers sublingual tirzepatide.
Full review →
FuturHealth
GLP-1 weight-loss platform combined with personalised nutrition and fitness coaching.
Editor’s take: Coaching is the differentiator. If you're going to use it, FuturHealth pulls ahead of cheaper, drug-only competitors. If you won't, save the money.
Full review →
Found
GLP-1 platform that pairs medication with one-on-one coaching and a broad off-label formulary.
Editor’s take: One of the more coaching-forward GLP-1 telehealth options. Pricing tiers can confuse first-time buyers; verify the cancellation terms before subscribing. Pricing tiers can confuse first-time buyers; verify the cancellation policy before subscribing. If you want the lowest possible cost for compounded GLP-1 without coaching, Trimi or HealthRx will be significantly cheaper.
Full review →
Strut Health
Broad-catalog telehealth covering hair, skin, weight loss, and sexual health, with free shipping and follow-ups bundled in.
Editor’s take: An efficient generalist. If you want depth in any one category, you'll find better. If you want breadth and a low management overhead, Strut Health is on the shortlist.
Full review →
Zealthy
Online GLP-1 care centered on insurance navigation, brand-name prescriptions and cash-pay semaglutide options.
Editor’s take: Zealthy pairs online weight-management care with insurance-navigation support and a cash-pay path. Its displayed $25–$151 monthly range is useful for comparison, but the endpoints carry different insurance and commitment conditions; confirm the exact medication, covered benefit, recurring fee, dose and renewal terms before paying.
Full review →2026 Price Comparison. Published Price Terms
Compare the lower and higher listed rates, then read the billing conditions. A listed monthly equivalent may require prepayment; visits, medication, membership, or shipping can cost extra.
Recorded price-check dates: 17 June 2026. Per-provider dates below; these are not a guarantee of today's checkout price.
Rates use different billing terms and are not necessarily all-in or month-to-month. Confirm total charges and cancellation terms. Compounded medications are not FDA-approved finished drugs; pharmacy type alone does not establish legality or clinical suitability.
3 providers · Trustpilot scores are customer opinions, not treatment results.
| Provider & billing terms | Lower listed rate | Higher listed rate | Pharmacy | Reviews & price check | Actions |
|---|---|---|---|---|---|
| SkinnyRxBest Value | Lower listed rate$149/mo | Higher listed rate$249/mo | PharmacyBrand Rx | 4.8/5 5,335 reviews 17 June 2026 | Go SkinnyRxRead full review |
| Shed Rx | Lower listed rate$199/mo | Higher listed rate$449/mo | PharmacyBrand Rx | 4.7/5 956 reviews 17 June 2026 | Go Shed RxRead full review |
| Found Health | Lower listed rate$129/mo | Higher listed rate$349/mo | PharmacyBrand Rx | 3.7/5 729 reviews 17 June 2026 | Go FoundRead full review |
Provider links may earn a commission. Rate sorting compares the displayed numbers, not equivalent treatment plans or total commitments. How we check price terms →
What to know before choosing
Zepbound (tirzepatide, Eli Lilly) has a retail list price of approximately $1,060-$1,400 per month without insurance. Eli Lilly's LillyDirect savings programme offers a cash-pay option of $550/month for eligible patients. In the SURMOUNT-1 trial (NEJM 2022), tirzepatide 15 mg achieved 20.9% mean weight loss at 72 weeks. Telehealth platforms that carry Zepbound on formulary often bundle the consultation fee, reducing total access cost. This guide breaks down every cost lever available in 2026.
Zepbound (tirzepatide) has a more complex pricing structure than Wegovy. Eli Lilly offers Zepbound through its direct-to-patient LillyDirect programme at $399–$549/month depending on dose — significantly below the $1,060/month list price. This direct programme bypasses traditional pharmacy channels and is available to patients without insurance or with insurance that does not cover Zepbound.
Through traditional pharmacies without insurance, Zepbound lists at approximately $1,060/month. GoodRx and manufacturer coupons can reduce this, but the LillyDirect programme is typically the lowest cash-pay option for most patients. Some telehealth platforms have integrated LillyDirect access into their prescribing workflow.
This guide covers every pricing pathway available for Zepbound without insurance, including the LillyDirect programme, pharmacy pricing, and telehealth platform pricing. We update it monthly as pricing changes.
Methodology
Pricing data is sourced from telehealth provider websites and verified as of June 2026. Retail pharmacy prices are sourced from GoodRx and Eli Lilly's official LillyDirect programme page.
Zepbound Without Insurance: The Real Cost Breakdown
Zepbound's list price of approximately $1,060/month is lower than Wegovy's, and Eli Lilly's savings programs are more accessible. Here is the complete picture of what Zepbound actually costs for different patient populations.
LillyDirect and the Savings Program
Eli Lilly's LillyDirect program offers Zepbound at $550/month for uninsured patients (any income level) and $25/month for commercially insured patients with coverage. The $550/month uninsured price is a significant reduction from the $1,060 list price and is available without income requirements — a meaningful difference from Novo Nordisk's WeGoSupport program.
The $25/month commercially insured price applies when the patient's insurance covers Zepbound. Prior authorization is typically required, and coverage criteria vary by plan.
Compounded Tirzepatide vs Brand-Name Zepbound
Compounded tirzepatide is available from telehealth clinics at $200–$450/month — more expensive than compounded semaglutide, reflecting higher API costs. Compared to LillyDirect's $550/month uninsured price for brand-name Zepbound, the cost advantage of compounded tirzepatide is narrower than it is for semaglutide.
For uninsured patients who do not qualify for savings programs, the cost comparison is: compounded tirzepatide at $200–$450/month vs. brand-name Zepbound at $550/month. The regulatory certainty and quality assurance of brand-name Zepbound may justify the premium for many patients.
Insurance Coverage Landscape
Commercial insurance coverage for Zepbound is expanding. The ADA's 2024 guidelines recommend GLP-1 therapy for patients with obesity and type 2 diabetes, which has improved coverage for the Mounjaro indication (same molecule). For weight management without diabetes, coverage depends on the specific plan.
Medicare coverage for Zepbound for cardiovascular risk reduction (following the SURMOUNT-MMO trial) is expected to expand coverage for Medicare-eligible patients with established cardiovascular disease. Telehealth clinics that track coverage changes and proactively notify patients of new coverage opportunities are providing ongoing value.
Zepbound is more accessible than its list price suggests, particularly through LillyDirect. The clinics in our top tier above help patients access savings programs and navigate insurance coverage for the most effective weight management medication currently available.
What the Studies Actually Show
Zepbound contains tirzepatide. The clinical evidence below is from the SURMOUNT-1 trial, which forms the basis of the FDA weight-management approval.
| Endpoint | Finding |
|---|---|
| Mean weight loss (SURMOUNT-1, 72 weeks, 15 mg)1 | −20.9% body weight vs −3.1% placebo in adults with obesity without diabetes |
| Mean weight loss with T2D (SURMOUNT-2, 72 weeks, 15 mg)2 | −14.7% body weight in adults with type 2 diabetes |
| Sleep apnea (SURMOUNT-OSA)3 | Tirzepatide reduced apnea-hypopnea index (AHI) by ~25–29 events/hour vs placebo at 52 weeks; FDA-approved labeling for moderate-to-severe OSA in obesity |
Frequently Asked Questions
What is the retail price of Zepbound without insurance?
The retail list price of Zepbound is approximately $1,060-$1,400 per month depending on dose and pharmacy. Eli Lilly's LillyDirect programme offers a cash-pay price of $550/month for eligible patients.
How can I reduce the cost of Zepbound?
The main cost levers are: (1) Eli Lilly's LillyDirect savings programme ($550/month cash-pay for eligible patients); (2) insurance prior authorisation with documentation of BMI 30 or higher, or 27 or higher with a comorbidity; (3) telehealth platforms that bundle the consultation fee with the prescription; (4) compounded tirzepatide from a 503A pharmacy as a lower-cost alternative under the personalisation exception.
Is compounded tirzepatide a cheaper alternative to Zepbound?
Yes. Compounded tirzepatide from a 503A pharmacy typically costs $99-$299 per month. However, the FDA's April 2026 proposed rule would restrict 503B compounding of tirzepatide. 503A compounding under the personalisation exception remains legal with a documented clinical justification.
- SURMOUNT-1 — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SURMOUNT-2 — Lancet 2023 · Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402(10402):613–626.
- SURMOUNT-OSA — NEJM 2024 · Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193–1205.
- SURPASS — program summary · Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503–515.
RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.